View : 402 Download: 0
The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
- Title
- The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
- Authors
- Kim, Sung-Yong; Bae, Sung Hwa; Bang, Soo-Mee; Eom, Ki-Seong; Hong, Junshik; Jang, Seongsoo; Jung, Chul Won; Kim, Hee-Jin; Kim, Ho Young; Kim, Min Kyoung; Kim, Soo-Jeong; Mun, Yeung-Chul; Nam, Seung-Hyun; Park, Jinny; Won, Jong-Ho; Choi, Chul Won
- Ewha Authors
- 문영철
- SCOPUS Author ID
- 문영철
- Issue Date
- 2021
- Journal Title
- KOREAN JOURNAL OF INTERNAL MEDICINE
- ISSN
- 1226-3303
2005-6648
- Citation
- KOREAN JOURNAL OF INTERNAL MEDICINE vol. 36, no. 1, pp. 45 - 62
- Keywords
- Polycythemia vera; Thrombocythemia, essential; Primary myelofibrosis; Practice guideline
- Publisher
- KOREAN ASSOC INTERNAL MEDICINE
- Indexed
- SCIE; SCOPUS; KCI
- Document Type
- Review
- Abstract
- In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional somatic mutations have a clinical impact on the prognosis of patients harboring these genetic abnormalities. Treatment strategies have also advanced with the introduction of JAK inhibitors, one of which has been approved for the treatment of patients with myelofibrosis and those with hydroxyurea-resistant or intolerant polycythemia vera. Recently developed drugs aim to elicit hematologic responses, as well as symptomatic and molecular responses, and the response criteria were refined accordingly. Based on these changes, we have revised the guidelines and present the diagnosis, treatment, and risk stratification of MPNs encountered in Korea.
- DOI
- 10.3904/kjim.2020.319
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML